Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Inv. presentation
PROGENICS PHARMACEUTICALS INC (PGNX) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/07/2020 8-K Quarterly results
03/13/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "PROGENICS PHARMACEUTICALS ANNOUNCES BUSINESS UPDATE AND THIRD QUARTER 2019 FINANCIAL RESULTS"
08/09/2019 8-K Quarterly results
Docs: "PROGENICS PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND BUSINESS UPDATE"
05/09/2019 8-K Quarterly results
Docs: "PROGENICS PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND BUSINESS UPDATE"
03/14/2019 8-K Quarterly results
Docs: "PROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE"
11/08/2018 8-K Quarterly results
Docs: "PROGENICS PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE"
07/31/2018 8-K Quarterly results
Docs: "FOLLOWING AZEDRA’ S APPROVAL, PROGENICS PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE"
05/09/2018 8-K Quarterly results
Docs: "PROGENICS PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE"
11/02/2017 8-K Quarterly results
Docs: "PROGENICS PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2017 FINANCIAL RESULTS AND BUSINESS UPDATE ● NDA for AZEDRA Submitted to the U.S. Food and Drug Administration on October 31st ● Positive Results from the Pivotal Phase 2b Study of AZEDRA Highlighted at Multiple Medical Conferences ● Clinical Trials for Prostate Cancer Product Candidates Continue to Advance ● Third Quarter 2017 RELISTOR Net Sales of $17.1 Million",
"Progenics Pharmaceuticals Completes Rolling Submission of NDA for AZEDRA ® in Pheochromocytoma and Paraganglioma"
08/09/2017 8-K Quarterly results
Docs: "PROGENICS PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2017 FINANCIAL RESULTS AND BUSINESS UPDATE ● NDA for AZEDRA ® Expected to be Submitted to U.S. Food and Drug Administration in August 2017 ● Results from Phase 2b Study of AZEDRA Accepted for Oral Presentation on September 1st at 2017 International Symposium on Pheochromocytoma and Paraganglioma ● Data Highlighting Potential Utility of Automated Bone Scan Index Presented at 2017 American Society of Clinical Oncology Annual Meeting in June ● Enrollment Ongoing in Clinical Trials for Prostate Cancer Product Candidates 1404, PyL™, and 1095 ● Second Quarter 2017 RELISTOR ® Net Sales of $17.3 Million"
05/04/2017 8-K Form 8-K - Current report
11/07/2016 8-K Quarterly results
Docs: "PROGENICS PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2016 FINANCIAL RESULTS AND BUSINESS UPDATE ● Received $50 Million Milestone Payment from Valeant Related to U.S. Approval of RELISTOR ® Tablets ● Commercial Launch of RELISTOR ® Tablets in September 2016 ● On November 4th , Monetized Portion of RELISTOR Royalty Stream through $50 Million Transaction ● Third Quarter 2016 RELISTOR Net Sales of $22.1 Million ● Ultra-Orphan Radiotherapeutic Candidate AZEDRA ® Registrational Trial Topline Results Expected First Quarter 2017 ● Advancing Phase 3 Trial for 1404 Toward Interim Analysis by End of This Year ● On Track to Initiate Phase 2/3 Trial of PyL™ Imaging Agent and Phase 1 Trial of 1095 This Year"
08/04/2016 8-K Quarterly results
Docs: "PROGENICS PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2016 FINANCIAL AND BUSINESS RESULTS"
05/05/2016 8-K Quarterly results
Docs: "FIRST QUARTER 2016 FINANCIAL AND BUSINESS RESULTS"
11/12/2013 8-K Quarterly results, Appointed a new director
Docs: "Tarrytown, NY, November 11, 2013"
08/09/2013 8-K Quarterly results
Docs: "PROGENICS PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2013 FINANCIAL RESULTS"
05/10/2013 8-K Quarterly results
Docs: "PROGENICS PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2013 FINANCIAL RESULTS"
03/15/2013 8-K Quarterly results
Docs: "PROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND YEAR-END 2012 FINANCIAL RESULTS"
11/08/2012 8-K Quarterly results
Docs: "PROGENICS 3Q 2012 OPERATING RESULTS"
08/09/2012 8-K Quarterly results
Docs: "PROGENICS 2Q 2012 OPERATING RESULTS"
05/08/2012 8-K Quarterly results
Docs: "PROGENICS 1Q 2012 OPERATING RESULTS"
11/09/2011 8-K Form 8-K - Current report
08/09/2011 8-K Form 8-K - Current report
05/10/2011 8-K Form 8-K - Current report
03/15/2011 8-K Form 8-K - Current report
11/08/2010 8-K Quarterly results
Docs: "PROGENICS SEPT 30, 2010"
08/09/2010 8-K Quarterly results
Docs: "PROGENICS JUNE 30, 2010"
05/10/2010 8-K Quarterly results
Docs: "PROGENICS MARCH 31, 2010"
03/15/2010 8-K Form 8-K - Current report
11/09/2009 8-K Form 8-K - Current report
08/06/2009 8-K Form 8-K - Current report
05/12/2009 8-K Form 8-K -- Current report
03/13/2009 8-K Form 8-K -- Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy